Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Apr 19, 2023 9:17pm
123 Views
Post# 35404250

RE:I love it!

RE:I love it!Well more shares bought in the PP by Andrew Schutte:

" After the issuance of the Shares pursuant to the Transactions, Mr. Schutte directly and indirectly owned and controlled 25,104,422 Shares, on a partially diluted basis (assuming conversion of the class A preference shares and exercise of all stock options and warrants), which represents 34.53% of the issued and outstanding Shares as of March 14, 2023, based on the aggregate of 72,704,366 Shares..." 
You combine this with Jamioe mackays precent share purcuase: 
After the issuance of the units pursuant to the transaction, Mr. Mackay directly and indirectly owned and controlled 14,896,107 shares.

Here is where we are at now: 
the aggregate of 72,704,366 Shares, which consists of: (i) 65,001,560 Shares outstanding as of March 14, 2023, (ii) 303,030 Shares that may be issuable on conversion of class A preference shares, (iii) 655,000 Shares that may be issuable on exercise of options and (iv) 6,744,776 Shares that may be issuable on exercise of warrants.

Do the math:  now Andrew and Jamie own approx. 55% of the company.
<< Previous
Bullboard Posts
Next >>